Saturday, July 18, 2020 2:50:34 AM
News on Alumni interviewed by the University itself. But of course it can be paid advertisement. I need to do DD to confirm it is not a paid advertisement.
https://mech.utah.edu/category/news/alumni-limelight/page/2/
Some here want to rate NP as high as Steve Jobs (check the link below) and believes NP, just like Jobs, does not have a degree but end up leading a small company to tremendous success. I have to admire the courage of people here coming out and praise Cydy in such a tremendous fashion. But instead of putting an equal sign between NP and Jobs right now, I think we should wait till Leron is approved. Once Leron is approved, we will definitely re-post the very encourage message that I am replying to so we all know how thoughtful that message is.
https://www.businessinsider.com/mark-zuckerberg-steve-jobs-tech-executives-never-graduated-college-dropouts-2019-5
A really really tremendous thought!!! Thank you for supporting Cydy CEO during this pandemic!!
https://mech.utah.edu/category/news/alumni-limelight/page/2/
Some here want to rate NP as high as Steve Jobs (check the link below) and believes NP, just like Jobs, does not have a degree but end up leading a small company to tremendous success. I have to admire the courage of people here coming out and praise Cydy in such a tremendous fashion. But instead of putting an equal sign between NP and Jobs right now, I think we should wait till Leron is approved. Once Leron is approved, we will definitely re-post the very encourage message that I am replying to so we all know how thoughtful that message is.
https://www.businessinsider.com/mark-zuckerberg-steve-jobs-tech-executives-never-graduated-college-dropouts-2019-5
A really really tremendous thought!!! Thank you for supporting Cydy CEO during this pandemic!!
Recent CYDY News
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
